114 results
6-K
EX-5.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
, fully paid and non-assessable. Except as expressly set forth herein, we have not undertaken any independent investigation to determine the existence
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … on Schedule 3.1(j), there is no action, suit, inquiry, notice of violation, proceeding or, to the knowledge of the Company, investigation pending
20-F/A
2023 FY
EX-2.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
, incurred by him as a result of an investigation or proceeding instituted against him by an authority empowered to conduct an investigation or proceedings
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
Center, or MD Anderson, we entered into an additional collaboration for the investigation of motixafortide in combination with KEYTRUDA in pancreatic … investigation plan agreed to by the relevant European authorities. This does not apply if the product is subject to an agreed waiver or deferral
F-3
ilzyzgffadm 2zi0q
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
ahli35f5o1
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
7g3hifx
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
27atsauffc 66v
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
hgqsegmog5jl0
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
0jovo6j
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
fvg0y
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-5.2
f56w64ew l5n
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-10.1
95ogs9xu
21 Sep 22
Current report (foreign)
8:00am
424B5
msl5vmnot
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
raktliu
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
qf15wn2w 1l27z9dv
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am